Noble Capital analyst Gregory Aurand downgraded Baudax Bio to Market Perform from Outperform without a price target. The Anjeso discontinuation disclosed last week was not unexpected given the reduction in commercial force earlier in 2022 but increases Baudax’s risk profile in the near term, Aurand tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BXRX:
- Baudax Bio initiates Phase II trial evaluating BX1000
- Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
- Baudax Bio Announces Closing of $5 Million Public Offering
- Baudax Bio Announces Pricing of $5 Million Public Offering
- Baudax Bio Announces 1-for-40 Reverse Stock Split
